Cargando…

Three-Year Outcomes in Kidney Transplant Recipients Switched From Calcineurin Inhibitor-Based Regimens to Belatacept as a Rescue Therapy

Background: The long-term benefits of conversion from calcineurin inhibitors (CNIs) to belatacept in kidney transplant recipients (KTr) are poorly documented. Methods: A single-center retrospective work to study first-time CNI to belatacept conversion as a rescue therapy [eGFR <30 ml/min/1.73 m(2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morel, Antoine, Hoisnard, Léa, Dudreuilh, Caroline, Moktefi, Anissa, Kheav, David, Pimentel, Ana, Sakhi, Hamza, Mokrani, David, Attias, Philippe, El Sakhawi, Karim, Champy, Cécile Maud, Remy, Philippe, Sbidian, Emilie, Grimbert, Philippe, Matignon, Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Health Archive
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043102/ https://www.ncbi.nlm.nih.gov/pubmed/35497889 http://dx.doi.org/10.3389/ti.2022.10228

Ejemplares similares

Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients
por: El Sakhawi, Karim, et al.
Publicado: (2020)

Belatacept inhibit human B cell germinal center development in immunodeficient mice
por: Samson, Chloé, et al.
Publicado: (2023)

Monotypic plasma cell interstitial nephritis as the only clinical manifestation in a patient with previously undiagnosed indolent multiple myeloma: A case report
por: Attias, Philippe, et al.
Publicado: (2016)

Additional Benefits of Rituximab and Plasma Exchange on Top of Standard Induction Therapy in Kidney Transplant Recipients With a Negative CDC Crossmatch but High Preformed Donor Specific Antibody Titer
por: Mohamadou, Inna, et al.
Publicado: (2023)

Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept
por: Schwarz, Chloë, et al.
Publicado: (2023)

CD44 staining in parietal epithelial cells and early steroid response in patients with minimal change disease
por: Morel, Antoine, et al.
Publicado: (2023)

Podocyte Injury in Lupus Nephritis
por: Sakhi, Hamza, et al.
Publicado: (2019)

Rituximab and Fibrillary Glomerulonephritis: Interest of B Cell Reconstitution Monitoring
por: Leibler, Claire, et al.
Publicado: (2018)

Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants
por: Kumar, Dhiren, et al.
Publicado: (2017)

Myosteatosis as an independent risk factor for mortality after kidney allograft transplantation: a retrospective cohort study
por: Morel, Antoine, et al.
Publicado: (2021)

Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination
por: Ivulich, Steven, et al.
Publicado: (2023)

Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
por: Tawhari, Ibrahim, et al.
Publicado: (2022)

HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers
por: Joher, Nizar, et al.
Publicado: (2021)

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
por: Hoisnard, Léa, et al.
Publicado: (2022)

Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France
por: Bertrand, Dominique, et al.
Publicado: (2023)

Preservation of Antiviral Immunologic Efficacy Without Alloimmunity After Switch to Belatacept in Calcineurin Inhibitor–Intolerant Patients
por: Schaenman, Joanna, et al.
Publicado: (2022)

Vaccination anti-COVID-19 chez les patients dialysés et transplantés rénaux
por: Sakhi, Hamza, et al.
Publicado: (2021)

Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters
por: Terrec, Florian, et al.
Publicado: (2019)

Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients
por: Attias, Philippe, et al.
Publicado: (2021)

Epidemiology, Risk Factors, and Outcomes of Opportunistic Infections after Kidney Allograft Transplantation in the Era of Modern Immunosuppression: A Monocentric Cohort Study
por: Attias, Philippe, et al.
Publicado: (2019)

Enhancing Beta Cell Replacement Therapies: Exploring Calcineurin Inhibitor-Sparing Immunosuppressive Regimens
por: Caldara, Rossana, et al.
Publicado: (2023)

Successful Treatment of Lung Calciphylaxis With Sodium Thiosulfate in a Patient With Sickle Cell Disease: A Case Report
por: Arrestier, Romain, et al.
Publicado: (2016)

The Cyclophilin-Dependent Calcineurin Inhibitor Voclosporin Inhibits SARS-CoV-2 Replication in Cell Culture
por: Ogando, Natacha S., et al.
Publicado: (2022)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System
por: Jourdain, Hugo, et al.
Publicado: (2022)

Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System
por: Jourdain, Hugo, et al.
Publicado: (2023)

A Multi-Modal Approach to Islet and Pancreas Transplantation With Calcineurin-Sparing Immunosuppression Maintains Long-Term Insulin Independence in Patients With Type I Diabetes
por: Wisel, Steven A., et al.
Publicado: (2023)

Assessment of Renal Transplant Perfusion by Contrast-Enhanced Ultrasound after Switch from Calcineurin Inhibitor to Belatacept: A Pilot Study
por: Osmanodja, Bilgin, et al.
Publicado: (2022)

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial
por: Bredewold, Obbo W., et al.
Publicado: (2022)

Phenotypic and Transcriptomic Lymphocytes Changes in Allograft Recipients After Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients
por: Pilon, Caroline, et al.
Publicado: (2020)

Kinetics of Anti–SARS-CoV-2 IgG Antibodies in Hemodialysis Patients Six Months after Infection
por: Sakhi, Hamza, et al.
Publicado: (2021)

De novo IgA vasculitis following adenovirus-based SARS-CoV-2 vaccination
por: Oniszczuk, Julie, et al.
Publicado: (2021)

Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept
por: Choi, Mira, et al.
Publicado: (2020)

Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014)

Impact of Calcineurin Inhibitor-Based Immunosuppression Maintenance During the Dialysis Period After Kidney Transplant Failure on the Next Kidney Graft Outcome: A Retrospective Multicenter Study With Propensity Score Analysis
por: Noelle, Juliette, et al.
Publicado: (2023)

Belatacept: Good, but not good enough?
por: Parameswaran, Sreejith, et al.
Publicado: (2012)

Belatacept: the challenges with transformational drugs
por: Vincenti, Flavio
Publicado: (2017)

Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS)
por: Pina Vegas, Laura, et al.
Publicado: (2022)

Renal Diseases Associated with Hematologic Malignancies and Thymoma in the Absence of Renal Monoclonal Immunoglobulin Deposits
por: Morel, Antoine, et al.
Publicado: (2021)

Treatment impact on COVID-19 evolution in hemodialysis patients
por: Chawki, Sylvain, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s4b71kqhm90s6318u6t88cotq5